Impact of GVHD prophylaxis on transplantation outcomes. Transplantation outcomes in 7/8 HLA-MMUD and 8/8 MUD HCT weighted samples with abatacept plus a CNI plus MTX vs CNI/MTX alone (A) or abatacept plus CNI/MTX vs PT-Cy-based GVHD prophylaxis (B) in the study from Kean et al. Error lines show the 95% confidence intervals. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001 for OS, RFS, NRM, and Rel comparisons between groups. NRM, nonrelapse mortality; Rel, relapse incidence; aGVHD III-IV, 180-day incidence of acute GVHD; cGVHD, chronic GVHD.